Sunshine Week is devoted to shining a light on the importance of public records and open government. Traditionally, though, it is the press and open government advocates that celebrate by writing ...

Eli Lilly (LLY) faces a downgrade to Reduce from HSBC analyst Rajesh Kumar, who cut his price target from $1,070 to $850, citing overestimated obesity drug market size ($80B-$120B by 2032 versus ...

Eli Lilly (LLY) shares slipped in the premarket on Tuesday after HSBC downgraded the weight loss drugmaker to Reduce from Hold, issuing the pharma giant’s only sell-equivalent rating on Wall Street, ...

Unruly Republic: The Epstein files were supposed to uncover Jeffrey Epstein’s sex-trafficking and blackmail operation. Instead they highlight how America’s liberal VIPs in media, tech and politics ...

Pay transparency is quietly reshaping how companies hire, pay and compete for talent — and many business owners aren’t fully prepared for what’s coming. Pay transparency is quietly reshaping hiring ...

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’s top growth stock picks. On February 18, Eli Lilly and Company (NYSE:LLY) said using Taltz (ixekizumab) together with Zepbound (tirzepatide) ...

Eli Lilly (LLY) announced on Wednesday that a late-stage trial designed to test a combination regimen containing its weight loss therapy Zepbound and psoriasis therapy Taltz reached the main goals.

Microsoft has acknowledged growing concerns about the lack of transparency in data center development. Tech companies in Wisconsin have been criticized for using anonymous LLCs and non-disclosure ...

Eli Lilly & Company (NYSE:LLY) ranks among the best high growth high margin stocks to buy now. Deutsche Bank retained its Buy rating and $1,200 price target for Eli Lilly & Company (NYSE:LLY) on ...

For decades, the ‘black box’ of corporate compensation has been the so-called final frontier of workplace secrecy. However, the arrival of the EU pay transparency directive represents more than a ...

Eli Lilly LLY announced that it entered a definitive agreement to acquire the privately held clinical-stage biotech Orna Therapeutics in a deal valued at $2.4 billion. This transaction includes both ...

This is read by an automated voice. Please report any issues or inconsistencies here. The Charter Reform Commission, a volunteer citizens panel, is looking at such ideas as increasing the size of the ...